Search results for "lcsh:Pharmacy and materia medica"

showing 10 items of 85 documents

Drug delivery of siRNA therapeutics

2020

Small interfering RNA (siRNA) is a class of nucleic acid-based drugs (NABDs) able to block gene expression by interaction with mRNA before its translation [...]

Messenger RNASmall interfering RNAChemistrysi-RNAlcsh:RS1-441Pharmaceutical ScienceTranslation (biology)Drug delivery; si-RNAlcsh:Pharmacy and materia medican/aEditorialDrug deliveryGene expressionDrug deliveryNucleic acidCancer research
researchProduct

Naringenin Nano-Delivery Systems and Their Therapeutic Applications

2021

Naringenin (NRG) is a polyphenolic phytochemical belonging to the class of flavanones and is widely distributed in citrus fruits and some other fruits such as bergamot, tomatoes, cocoa, and cherries. NRG presents several interesting pharmacological properties, such as anti-cancer, anti-oxidant, and anti-inflammatory activities. However, the therapeutic potential of NRG is hampered due to its hydrophobic nature, which leads to poor bioavailability. Here, we review a wide range of nanocarriers that have been used as delivery systems for NRG, including polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nanosuspensions, and nano…

Naringeninnatural productsnaringeninlcsh:RS1-441Pharmaceutical ScienceReview02 engineering and technologyPharmacologylcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalSolid lipid nanoparticleflavonoidnutraceuticalsLiposomeChemistryfood and beverages021001 nanoscience & nanotechnologynanomedicineBioavailabilityantioxidants030220 oncology & carcinogenesisdrug deliveryDrug deliveryNanomedicinenanoparticlesNanocarriersbioavailability0210 nano-technologyPharmaceutics
researchProduct

Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

2020

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic model for nimotuzumab and to identify demographic and clinical predictive factors of the pharmacokinetic variability. The population pharmacokinetics (PopPK) of nimotuzumab was characterized using a nonlinear mixed-effect modeling approach with NONMEM&reg

Oncologymedicine.medical_specialtyEGFRPopulationAutosomal dominant polycystic kidney diseasePharmaceutical SciencePhases of clinical researchlcsh:RS1-441030226 pharmacology & pharmacyArticlesemi-mechanistic pharmacokineticslcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicinepopulation analysismedicinePolycystic kidney diseaseNimotuzumabEpidermal growth factor receptoreducationNONMEMeducation.field_of_studybiologyautosomal dominant polycystic kidney diseasebusiness.industrynimotuzumabmedicine.diseaseNONMEM030220 oncology & carcinogenesisbiology.proteinbusinessmedicine.drugPharmaceutics
researchProduct

Population Pharmacokinetics of Palbociclib in aReal-World Situation

2021

Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Its metabolism profile is associated with an important interpatient variability. We performed a population pharmacokinetics study of palbociclib in women routinely followed in a cancer center. One hundred and fifty-one samples were analyzed. The sampling times after administration ranged from 0.9 to 75 h and the samples were taken between 1 and 21 days after the beginning of the palbociclib cycle. Palbociclib was determined using a validated mass spectrometry method. The best model that described the concentrat…

Oncologymedicine.medical_specialtypalbociclibPharmaceutical ScienceRenal functionlcsh:Medicinelcsh:RS1-441Population pharmacokineticsAbsorption (skin)Palbociclib030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineLag timepopulation pharmacokineticsInternal medicineDrug Discoverymedicinereal-world situationDosingPostmenopausal womenbusiness.industrylcsh:Rmedicine.diseaseMetastatic breast cancer030220 oncology & carcinogenesisMolecular MedicinebusinessPharmaceuticals
researchProduct

Optimization of Innovative Three-Dimensionally-Structured Hybrid Vesicles to Improve the Cutaneous Delivery of Clotrimazole for the Treatment of Topi…

2019

New three-dimensionally-structured hybrid phospholipid vesicles, able to load clotrimazole in a high amount (10 mg/mL), were obtained for the first time in this work by significantly reducing the amount of water (&le

PhospholipidPharmaceutical Sciencelcsh:RS1-44102 engineering and technology030226 pharmacology & pharmacyArticleclotrimazolelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivophospholipid vesiclesX-raysCandida albicansElectron microscopymedicineGlycerolskin deliveryCandida albicansco-solventsPhospholipidsChromatographybiologyClotrimazoleSmall-angle X-ray scatteringVesicle021001 nanoscience & nanotechnologybiology.organism_classification<i>Candida albicans</i>Microscòpia electrònicachemistryTransmission electron microscopyfungal infectionsRaigs X0210 nano-technologyFosfolípidsmedicine.drugPharmaceutics
researchProduct

Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice

2020

MBQ-167 is a dual inhibitor of the Rho GTPases Rac and Cdc42 that has shown promising results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in vitro and in vivo in metastatic breast cancer mouse models. The aim of this study is to develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK-PD) model of MBQ-167 to predict tumor growth inhibition following intraperitoneal (IP) administration in mice bearing Triple Negative and HER2+ mammary tumors. PBPK and Simeoni tumor growth inhibition (TGI) models were developed using the Simcyp V19 Animal Simulator. Our developed PBPK framework adequately describes the time course of MBQ-167 in each of the mo…

Physiologically based pharmacokinetic modellinglcsh:RS1-441Pharmaceutical ScienceSpleenPharmacologyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinebreast cancerPharmacokineticsIn vivomedicinePotency030304 developmental biology0303 health sciencesMammary tumorbusiness.industryMBQ-167medicine.diseaseMetastatic breast cancermedicine.anatomical_structure030220 oncology & carcinogenesisPharmacodynamicsRac inhibitorphysiologically based pharmacokinetic modelingbusinessPharmaceutics
researchProduct

Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder …

2020

Background: The aim of this analysis was to characterize the pharmacokinetics (PK) of sublingual buprenorphine (BUP) and its metabolites (buprenorphine glucuronide

PopulationCmaxbuprenorphine/naloxone sublingual filmlcsh:RS1-441Pharmaceutical SciencePharmacology030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticspopulation pharmacokineticsNaloxonemedicine030212 general & internal medicineDosingNorbuprenorphinePuerto Ricanseducationeducation.field_of_studyopioid use disorder (OUD)business.industrypopPKchemistryGlucuronidebusinessSuboxonepharmacokineticsmedicine.drugBuprenorphinecompartmental modelingPharmaceutics
researchProduct

Oxidative stress in preterm infants: Overview of current evidence and future prospects

2020

Preterm birth (PTB), defined as parturition prior to 37 weeks of gestation, is the leading cause of morbidity and mortality in the neonatal population. The incidence and severity of complications of prematurity increase with decreasing gestational age and birthweight. The aim of this review study is to select the most current evidence on the role of oxidative stress in the onset of preterm complication prevention strategies and treatment options with pre-clinical and clinical trials. We also provide a literature review of primary and secondary studies on the role of oxidative stress in preterm infants and its eventual treatment in prematurity diseases. We conducted a systematic literature s…

PopulationMEDLINEPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441ReviewBioinformaticsmedicine.disease_causelcsh:Pharmacy and materia medicaPretermDrug DiscoverymedicineProspective cohort studyeducationeducation.field_of_studybusiness.industrylcsh:RGestational ageClinical trialFuture prospectsOxidative stressInclusion and exclusion criteriaFuture prospectMolecular MedicineGestationAntioxidantbusinessOxidative stress
researchProduct

Phosphonic Acid Analogues of Phenylglycine as Inhibitors of Aminopeptidases: Comparison of Porcine Aminopeptidase N, Bovine Leucine Aminopeptidase, T…

2019

The inhibitory activity of 14 racemic phosphonic acid analogs of phenylglycine, substituted in aromatic rings, towards porcine aminopeptidase N (pAPN) and barley seed aminopeptidase was determined experimentally. The obtained patterns of the inhibitory activity against the two enzymes were similar. The obtained data served as a basis for studying the binding modes of these inhibitors by pAPN using molecular modeling. It was found that their aminophosphonate fragments were bound in a highly uniform manner and that the difference in their affinities most likely resulted from the mode of substitution of their phenyl rings. The obtained binding modes towards pAPN were compared, with these predi…

aminophosphonateMolecular modelStereochemistryPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441AminopeptidaseArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineDrug Discoveryinhibitorsaminopeptidases030304 developmental biologychemistry.chemical_classification0303 health sciencesChemistrymolecular modelingAminopeptidase Nlcsh:RAromaticityAffinitiesEnzymefluorine substitutedAminophosphonate030220 oncology & carcinogenesisMolecular Medicinephenylglycine analoguesLeucinePharmaceuticals
researchProduct

Synthesis of curcumin derivatives and analysis of their antitumor effects in triple negative breast cancer (TNBC) cell lines

2019

We analyzed antitumor effects of a series of curcumin analogues. Some of them were obtained by reaction of substitution involving the two phenolic OH groups of curcumin while the analogues with a substituent at C-4 was prepared following an original procedure that regards the condensation of benzenesulfenic acid onto the nucleophilic central carbon of the curcumin skeleton. We analyzed cytotoxic effects of such derivatives on two TNBC (triple negative breast cancer) cell lines, SUM 149 and MDA-MB-231, but only three of them showed an IC50 in a lower micromolar range with respect to curcumin. We also focused on these three derivatives that in both cell lines exhibited a higher or at least eq…

antiproliferative activitySubstituentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441antioxidant activityprooxidant activitylcsh:Pharmacy and materia medicapro-apoptotic activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoveryCytotoxic T cellNF-κB inhibitionAntioxidant activity Antiproliferative activity NF-κB inhibition Pro-apoptotic activity Prooxidant activity Sulfenic acidIC50Triple-negative breast cancer030304 developmental biology0303 health sciencesCommunicationlcsh:Rsulfenic acidchemistryCell culture030220 oncology & carcinogenesisCancer researchCurcuminSettore BIO/14 - FarmacologiaMolecular MedicineSulfenic acidLead compound
researchProduct